Digestive diseases (Basel, Switzerland)
Cure8 research brief
Why This Matters
People with IBD who need weight loss or have metabolic problems may encounter GLP-1 receptor agonists; this review suggests those drugs reduced weight and improved metabolic measures in people with IBD without clear signal of worsening disease activity in the available studies.
Who Should Pay Attention
Adults with IBD and metabolic comorbidities, gastroenterologists, and researchers interested in metabolic interventions for IBD.
Study Snapshot
Story typeResearch paper
Evidence typeSystematic review
Source depthJournal abstract
What To Know
This paper is a systematic review and single-arm meta-analysis of studies that used GLP-1 receptor agonists (GLP-1 RAs) in people with inflammatory bowel disease (IBD). The analysis pooled weight and metabolic outcomes (BMI, weight loss percentage, LDL, HbA1c) and also reported IBD-related activity markers (fecal calprotectin) and adverse events.
The pooled results reported meaningful average weight loss (about −7.6% total weight loss) and improvements in some metabolic measures; fecal calprotectin averaged lower in treated patients and relatively few patients required IV steroids or escalation to advanced IBD therapy in the included studies.
Nausea and vomiting were the most commonly reported adverse events. The authors conclude GLP-1 RAs may reduce weight and improve metabolic measures without clearly worsening IBD activity, but they emphasize the need for larger randomized controlled trials to establish causality and long-term safety.
Keep In Mind
Findings are drawn from the article abstract and pooled, mostly non-randomized data; the authors and Cure8 note larger randomized trials are needed before changing standard care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Systematic review
Evidence type derived from source or registry metadata.
PublicationDigestive diseases (Basel, Switzerland)
AuthorsOmar Khasawneh, Kyrillos Mahrous Gerges, Islam Khasawneh +10 more
InstitutionDepartment of Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Study typeJournal article, systematic review
Indexed viaPubMed
Source typeResearch paper
PublishedAug 18, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prospective Evaluation of Ustekinumab Dose Intensification in Inflammatory Bowel Diseases.
Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...
Dose‐escalated biologic therapy improves outcomes in people with inflammatory bowel disease
People on biologic therapy who are not responding to standard doses may benefit from dose escalation — this study suggests escalation is common in routine care and linked with improved objective and patient‑reported...
Dose-escalated biologic therapy improves outcomes in people with inflammatory bowel disease.
For people with IBD who do not respond to standard biologic doses, escalating the dose appears common in routine care and was associated with better short-term remission rates and reduced healthcare use in this registry...